Literature DB >> 7040847

Chylomicronemia syndrome. Interaction of genetic and acquired hypertriglyceridemia.

J D Brunzell, E L Bierman.   

Abstract

Chylomicrons accumulating in plasma obtained after an overnight fast are always abnormal and can be detected in association with triglyceride levels above 1000 mg per dl. The chylomicronemia syndrome is associated with marked hypertriglyceridemia (plasma triglyceride level above 2000 mg per dl), abdominal pain or pancreatitis, eruptive xanthomata, lipemia retinalis, dyspnea, mental aberrations, and other minor findings. The marked hypertriglyceridemia is usually due to the interaction of a common familial form of hypertriglyceridemia and a common acquired form of hypertriglyceridemia secondary to another disease, drug, or alcohol. Rarely, genetic abnormalities in lipoprotein lipase are the cause of the marked hypertriglyceridemia. Therapy that successfully lowers plasma triglyceride levels is associated with clearing of the symptoms and signs of the chylomicronemia syndrome and prevention of its recurrence.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7040847     DOI: 10.1016/s0025-7125(16)31430-4

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  19 in total

1.  The effect of L-asparaginase on lipid metabolism during induction chemotherapy of childhood lymphoblastic leukaemia.

Authors:  P Cremer; M Lakomek; W Beck; G Prindull
Journal:  Eur J Pediatr       Date:  1988-01       Impact factor: 3.183

2.  Hypertriglyceridaemia and abnormalities of triglyceride catabolism persisting after pancreatitis.

Authors:  P N Durrington; O P Twentyman; J M Braganza; J P Miller
Journal:  Int J Pancreatol       Date:  1986-10

Review 3.  The effects of diuretics and adrenergic-blocking agents on plasma lipids.

Authors:  J J Rohlfing; J D Brunzell
Journal:  West J Med       Date:  1986-08

4.  Plasma and lipoprotein lipid responses to four hypolipid drugs.

Authors:  W R Hazzard; P W Wahl; C Gagne; D Applebaum-Bowden; G R Warnick; J J Albers
Journal:  Lipids       Date:  1984-02       Impact factor: 1.880

Review 5.  Chylomicronaemia--current diagnosis and future therapies.

Authors:  Amanda J Brahm; Robert A Hegele
Journal:  Nat Rev Endocrinol       Date:  2015-03-03       Impact factor: 43.330

6.  Diagnostic evaluation of acute pancreatitis in two patients with hypertriglyceridemia.

Authors:  Yoshifumi Okura; Kozo Hayashi; Tetsuji Shingu; Goro Kajiyama; Yoshiyuki Nakashima; Keijiro Saku
Journal:  World J Gastroenterol       Date:  2004-12-15       Impact factor: 5.742

7.  A case of hypothyroidism and type 2 diabetes associated with type V hyperlipoproteinemia and eruptive xanthomas.

Authors:  Jeong Rang Park; Tae Sik Jung; Jung Hwa Jung; Gyeong-Won Lee; Me Ae Kim; Ki-Jong Park; Deok Ryong Kim; Se-Ho Chang; Soon Il Chung; Jong Ryeal Hahm
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

8.  Chylomicron-retinyl palmitate clearance in type I hyperlipidemic families.

Authors:  D L Sprecher; S L Knauer; D M Black; L A Kaplan; A A Akeson; M Dusing; D Lattier; E A Stein; M Rymaszewski; D A Wiginton
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

Review 9.  Lipoprotein size and susceptibility to atherosclerosis--insights from genetically modified mouse models.

Authors:  Murielle M Véniant; Anne P Beigneux; André Bensadoun; Loren G Fong; Stephen G Young
Journal:  Curr Drug Targets       Date:  2008-03       Impact factor: 3.465

10.  Lipoprotein lipase activity and mass, apolipoprotein C-II mass and polymorphisms of apolipoproteins E and A5 in subjects with prior acute hypertriglyceridaemic pancreatitis.

Authors:  Inmaculada Coca-Prieto; Pedro Valdivielso; Gunilla Olivecrona; María José Ariza; José Rioja; Pilar Font-Ugalde; Carlota García-Arias; Pedro González-Santos
Journal:  BMC Gastroenterol       Date:  2009-06-17       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.